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Introduction
The clinical triad pyoderma gangrenosum (PG), Acne, 
and hidradenitis suppurativa (HS), known as PASH 
syndrome, is a recently described entity that forms 
part of the spectrum of autoinflammatory diseases 
(ADs), [1]. ADs are a set of illnesses that cause 
systemic inflammation due to a dysregulation in the 
innate immune system [2]. We report a case of PASH 
syndrome in a patient with end-stage renal disease 
(ESRD) who was successfully treated with the tumor 
necrosis factor (TNF) inhibitor, adalimumab.
Case Report
A 42-year-old man presented with a 2-year history 
of painful skin lesions affecting his upper and lower 
extremities, trunk, and groin area. The lesions started 
out as pustules, coalesced into abscesses, and 
eventually broke down to form ulcers. The patient’s 
medical history was significant for ESRD owing to 
focal segmental glomerulosclerosis with subsequent 
hypertension. Chronic medication consisted of 
furosemide, amlodipine, and atenolol.
He had been suffering from acne since the age of 
16 and was diagnosed with HS at age 30, which 
was surgically treated in both axillae. He denied any 
relevant family history of skin disease. On systemic 
review the patient reported no constitutional 
symptoms and specifically denied arthralgia or 
gastrointestinal (GI) symptoms.
He consulted numerous primary care physicians over 
the course of 2 years, who treated him with multiple 
antibiotics and antifungals with no response. He 
was also prescribed a superpotent topical steroid 
(clobetasol propionate 0.05% ointment) with a 
partial response.
On physical examination, he had multiple 
erythematous plaques consisting of nodules, 
abscesses, draining sinuses, ulceration, and cribriform 
scarring distributed over both upper extremities and 
inner thighs (Figure 1 A). Surgical scars were evident 
Abstract
PASH syndrome (pyoderma gangrenosum, acne, and 
suppurative hidradenitis) forms part of the spectrum 
of autoinflammatory diseases. We report an unusual 
case of PASH syndrome in a patient with end-stage 
renal disease (ESRD) who was successfully treated 
with the tumor necrosis factor inhibitor, adalimumab. 
The case underscores the challenges associated 
with the treatment of PASH syndrome as well as the 
ongoing search to establish a genetic basis for the 
syndrome. Renal impairment has been reported in 
association with pyoderma gangrenosum but has not 
been described in PASH syndrome. We believe this to 
be the first reported case of a patient who developed 
PASH syndrome in the setting of ESRD.
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in both axillae (Figure 1A) with active Hurley stage 
III HS in the inguinal area. Prominent acne scarring 
was also visible on the patient’s face (Figure 1B) and 
he had multiple comedones and post inflammatory 
hyperpigmentation over the chest and back (Figure 
1C).
Histological examination of biopsies taken from the 
lesions on his upper extremities showed nodular 
suppurative granulomatous inflammation with 
sinus formation (Figure 2). Special stains to rule out 
infections were all negative including a Ziehl-Neelsen, 
Brown-Hopps gram, and periodic acid-Schiff stain.
Bacterial culture showed only mild growth of Proteus 
mirabilis, which was considered as secondary 
colonization. Mycology culture of tissue showed no 
fungal growth.
A diagnosis of PG was made based on the histology 
and the clinical presentation of painful chronic 
erythematous plaques, with sinus formation and 
shallow ulceration. Other causes of cutaneous 
ulceration were ruled out and the patient fulfilled 
international proposed criteria for the vegetative 
subtype of PG [3]. In the setting of acne and HS the 
patient was diagnosed with PASH syndrome.
The patient was further investigated to rule out 
any PG-associated disease. A lower gastrointestinal 
endoscopy ruled out any inflammatory bowel disease 
and serum and urine protein electrophoresis showed 
no signs of hematologic malignancy or monoclonal 
gammopathy. The rheumatoid factor was negative.
Genetic studies in this patient involved whole exome 
sequencing with a specific focus on variants in genes 
Figure 1. A) Multiple erythematous plaques consisting of nodules, 
abscesses, draining sinuses, ulceration and cribriform scarring 
distributed over both upper extremities. Surgical scars are evident 
in both axillae from previous hidradenitis suppurativa surgery. B) 
Multiple comedones and post inflammatory hyperpigmentation 
over his back. C) Prominent acne scarring was also visible on his 
face.
	
Figure 2. A) Nodular infiltrate of suppurative granulomatous 
inflammation. H&E, 4%. B) Follicular plugging, marked 
hyperplasia of follicular epithelium and a dense infiltrate of 
lymphocytes, macrophages, plasma cells and neutrophils. H&E, 
4%. C) Intraepithelial pustule-containing mature neutrophils. 
H&E, 10%.
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previously reported in inflammatory pathways 
and autoinflammatory syndromes (Table 1). The 
variants that were identified in these genes (Table 
2), however, are all commonly found in the general 
population (allele frequency > 1%).
The patient was initiated on prednisone 40mg 
once daily and doxycycline 100mg twice daily. 
He was encouraged to continue with topical 
clobetasol propionate 0.05% ointment and to use an 
antibacterial wash in the areas affected by HS.
After 4 months, the patient’s PG showed significant 
improvement on this treatment but the HS lesions 
only showed partial improvement with persistent 
drainage from the inguinal area.
As a consequence of the long-term high dose systemic 
corticosteroid intake he developed a significant 
GI hemorrhage, requiring blood transfusion and 
hospitalization; he developed prominent cushingoid 
features.
Prednisone was weaned. Simultaneously doxycycline 
was changed to rifampicin 600mg daily and 
clindamycin 300mg BID. The patient’s PG flared owing 
to the reduced dose of prednisone and the HS lesions 
did not respond to the change in antibiotics. Because 
of the patient’s renal impairment conventional 
immunosuppressive drugs like methotrexate and 
cyclosporine were contraindicated and he was 
commenced on adalimumab. This was given 160 mg 
subcutaneously at week 0, 80 mg at week 2, and 40 
mg weekly for weeks 4-8.
The patient showed a remarkable response at 8-weeks 
(Figure 3). He experienced complete remission of his 
PG lesions and achieved a Hidradenitis Suppurativa 
Clinical Response (HiSCR). HiSCR is defined as a ≥ 
50% reduction in inflammatory lesion count and no 
increase in abscesses or draining fistulas in HS when 
compared with baseline [4].
Case Discussion: PASH syndrome was first described by 
Braun-Falco et al. in 2012 as a new autoinflammatory 
Table 1. Genes involved in inflammatory pathways and skin 
diseases.
Year Disease Gene
1997 Familial Mediterranean Fever (FMF) MEFV
1999 TNF-Receptor Associated Periodic Syndrome (TRAPS) TNFRSF1A
1999 Hyper IgD Syndrome (HIDS) MVK
2001 Cryopyrin Associated Periodic Syndromes (CAPS) NLRP3 (CIAS1)
2001 Blau Syndrome NOD2
2001 Cherubism SH3BP2
2002 Pyogenic sterile Arthritis, Pyoder-ma gangrenosum and Acne (PAPA) PSTPIP1
2004 Early Onset Sarcoidosis (EOS) NOD2
2005 Majeed Syndrome LPIN2
2006 Recurrent Hydatidiform Mole 1 (RHM1) NLRP7
2008 Familial Cold Autoinflammatory Syndrome 2 (FCAS2) NLRP12
2009 Deficiency of IL-1 Receptor Antag-onist (DIRA) IL1RN
2009 Severe infantile inflammatory bowel disease
IL10RA, IL10RB, 
IL10
2011 CANDLE/JMP/NNS PSMB8
2011 Deficiency of IL36 Receptor Antag-onist (DITRA) IL36RN
2012
Autoinflammation & PLCγ2-as-
sociated antibody deficiency & 
immune dysregulation (APLAID)
PLCG2
2012 HOIL1 Deficiency RBCK1 (HOIL1)
2013 Pustular psoriasis/ pityriasis rubra pilaris CARD14
Table 2. Genes with common variants that were identified in the 
patient.
Gene Variant
CARD14 R547S
IL10RA R351G
MEFV G436R
D424E
NLRP7 G487E
V391I
NOD2 P268S
R702W
PSMB8 G8R
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syndrome related to PAPA syndrome (Pyogenic 
Arthritis, Pyoderma gangrenosum, and Acne) but 
distinct owing to the absence of pyogenic arthritis 
and an association with HS [1].
Monogenic ADs are associated with different 
mutations in the interleukin-1β (IL-1β) pathway, 
leading to an overproduction of IL-1β. This triggers 
the release of proinflammatory cytokines and 
chemokines, which leads to the recruitment and 
activation of neutrophils, causing a neutrophil-
mediated inflammation [4].
Immunological studies confirmed this over 
expression of the main proinflammatory cytokines 
in PG lesions of PASH patients namely IL-1β and its 
receptors, TNF and IL-17 [5].
Although mutations in genes commonly associated 
with ADs have been identified in PASH syndrome 
(Table 3), a genetic basis for the syndrome is still not 
fully established [6, 7]. Our genetic analysis identified 
some common variants in genes previously reported 
in inflammatory pathways and ADs but failed to 
identify a definitive causative factor. An increased 
number of CCTG repeats in the PSTPIP1 promotor 
was reported in the first two cases of PASH syndrome 
[1] but this was not demonstrated in this patient.
PG can be associated with inflammatory 
bowel disease, hematological 
malignancies, monoclonal gammopathy 
and rheumatoid arthritis but extensive 
investigations ruled these out. An 
association of PG and ESRD has been 
described in isolated case reports [8, 9] 
and a retrospective study that analyzed 
data from 49 patients with pyoderma 
gangrenosum showed that 18.4 % had 
renal insufficiency [10]. Despite this 
established association between PG and 
renal impairment we believe this to be the 
first reported case of PASH syndrome in a 
patient with ESRD.
ESRD gives rise to various cytokine 
disturbances and to a state of 
hypercytokinemia owing to reduced 
removal rate as well as increased cytokine 
generation [11]. Whether this contributed 
to the clinical manifestations of PASH syndrome in 
our patient remains to be proven.
The treatment of PASH syndrome remains 
problematic as conventional immunosuppressive 
therapies often fail to provide satisfactory results [7]. 
In our case some of the PG lesions showed a response 
to topical clobetasol propionate 0.05% ointment. This 
supports recent evidence that PG may be controlled 
effectively using topical agents like superpotent 
topical steroids, depending on the size of the lesion 
[12]. The patient showed significant improvement 
in his PG lesions in response to a combination of 
systemic corticosteroids and doxycycline, but the HS 
lesions only showed a partial response.
Isolated case reports showed the TNF inhibitors 
infliximab and adalimumab to be effective in the 
treatment of PASH syndrome [1, 13-16]. Adalimumab 
has been successfully used in renal failure and found 
not to worsen renal function, even in the setting of 
hemodialysis [17]. The patient responded remarkably 
well to adalimumab and had complete remission of 
his PG lesions and achieved HiSCR within 8 weeks. 
Anakinra, an IL-1 receptor antagonist, is another 
treatment option that is showing great promise [5].
	
Figure 3. PG and HS lesions showing marked improvement after 8 weeks of 
adalumimab treatment. Right forearm at diagnosis (A) and at 8 weeks (B). Left 
upper thigh at diagnosis (C) and at 8 weeks (D).
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Table 3. A summary of the published cases of PASH syndrome including this case.
Case Sex Age at diagnosis Comorbidities BMI Smoker
Gene 
mutation Treatment Response Reference
1 M 48 None NR Yes
PSTPIP1
Topical and oral CS Partial remission
Caldereron-Castrat et al
2016
2. F 32 PCOS 39 No - CS, Dapsone, Rifampicin, Ciprofloxacin
Substantial improvement 
in PG. Zivanovic et al 2016
3 M 24 Temporomandibular Joint Ankylosis NR NR -
Systemic CS, Doxycyl-
cine, amoxicillin/clavulin 
acid.
Improvement of PG Wargo et al 2016
4 F 22 None 36.7 No - Infliximab, cyclosporine, dapsone Complete remission Staub et al 2015
5. F 26 Ulcerative colitis with collectomy NR No - Adalumimab Partial remission Murphy et al 2015
6 M 23 None NR Yes - NR NR Duchatelet et al 2015
7 M 37 None NR Yes - NR NR Duchatelet et al 2015
8 F 29 None NR No
NCSTN
NR NR Duchatelet et al 2015
9 F 45 Cervicobrachial pain NR NR
MEFV
NOD2
Infliximab Partial remission Marzano et al 2014
10 M 23 Crohn disease NR NR - Adalumimab Complete remission Marzano et al 2014
11 M 43 Spondyloarthritis NR NR PSMB8 Infliximab Partial remission Marzano et al 2014
12 M 34 None 31.1 Yes - Isotretinoin, anakinra, ciclosporin Partial remission Braun-Falco et al 2012
13 M 44 None 33.8 Yes - Topical tacrolimus, oral CS, azathioprine Partial remission Braun-Falco et al 2012
14 M 33 Spondyloarthritis NR NR - Infliximab, isoniazid Partial remission Bruzzese et al 2012
15 M 34 Bariatric surgery >40 NR - Infliximab Partial remission Marzano et al 2012
16 M 42 Chronic Renal Failure >40 No - Adalumimab Complete remission Current Case
CS, corticosteroids; NR, Not Reported;
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Conclusion
This case highlights the challenges associated with 
the treatment of PASH syndrome and affirms the use 
of adalimumab as an effective treatment option. ESRD 
may be a contributing factor in the development of 
PASH syndrome but this association needs further 
investigation. Our case supports the hypothesis that 
PASH syndrome may not be a monogenic disease but 
rather a disease with genetic heterogeneity.
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